miltefosine has been researched along with Chagas Disease in 19 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Chagas Disease: Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Trypanosoma cruzi, the Chagas disease etiological agent, is sensitive to APs (edelfosine, miltefosine and ilmofosine) in vitro." | 3.91 | In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects. ( Barrias, E; Calogeropoulou, T; de Souza, W; Reignault, LC, 2019) |
| "We have previously shown that 3-nitro-1H-1,2,4-triazole-based arylamides and arylsulfonamides demonstrate significant activity in vitro against Trypanosoma cruzi, the causative parasite of Chagas disease." | 3.80 | Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. ( Bloomer, WD; Kaiser, M; Papadopoulou, MV; Rosenzweig, HS; Wilkinson, SR, 2014) |
| "Amiodarone is also capable to inhibit the oxidosqualene cyclase, a key enzyme in the synthesis of ergosterol." | 2.47 | Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. ( Benaim, B; Garcia, CR, 2011) |
| "Chagas Disease is caused by infection with the insect-transmitted protozoan Trypanosoma cruzi and affects more than 10 million people." | 1.51 | Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model. ( Costa, A; López, C; Marín, C; Martín-Escolano, R; Martin-Montes, Á; Medina-Carmona, E; Rotger, C; Sánchez-Moreno, M; Vega, M, 2019) |
| " This alkylphospholipid was also extremely toxic against intracellular amastigotes of both strains." | 1.31 | Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. ( Bozza, MT; Freire-De-Lima, CG; Gibaldi, D; Heise, N; Mendonça-Previato, L; Previato, JO; Saraiva, VB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Boiani, M | 1 |
| Boiani, L | 1 |
| Merlino, A | 1 |
| Hernández, P | 1 |
| Chidichimo, A | 1 |
| Cazzulo, JJ | 1 |
| Cerecetto, H | 1 |
| González, M | 1 |
| Papadopoulou, MV | 5 |
| Trunz, BB | 1 |
| Bloomer, WD | 5 |
| McKenzie, C | 1 |
| Wilkinson, SR | 5 |
| Prasittichai, C | 1 |
| Brun, R | 3 |
| Kaiser, M | 7 |
| Torreele, E | 1 |
| Patrick, DA | 1 |
| Ismail, MA | 1 |
| Arafa, RK | 1 |
| Wenzler, T | 1 |
| Zhu, X | 1 |
| Pandharkar, T | 1 |
| Jones, SK | 1 |
| Werbovetz, KA | 1 |
| Boykin, DW | 1 |
| Tidwell, RR | 1 |
| Rosenzweig, HS | 4 |
| O'Shea, IP | 2 |
| Chatelain, E | 2 |
| Ioset, JR | 1 |
| Szular, J | 1 |
| Linciano, P | 1 |
| Moraes, CB | 1 |
| Alcantara, LM | 1 |
| Franco, CH | 1 |
| Pascoalino, B | 1 |
| Freitas-Junior, LH | 1 |
| Macedo, S | 1 |
| Santarem, N | 1 |
| Cordeiro-da-Silva, A | 1 |
| Gul, S | 1 |
| Witt, G | 1 |
| Kuzikov, M | 1 |
| Ellinger, B | 1 |
| Ferrari, S | 1 |
| Luciani, R | 1 |
| Quotadamo, A | 1 |
| Costantino, L | 1 |
| Costi, MP | 1 |
| Thompson, AM | 1 |
| O'Connor, PD | 1 |
| Marshall, AJ | 1 |
| Blaser, A | 1 |
| Yardley, V | 2 |
| Maes, L | 3 |
| Gupta, S | 1 |
| Launay, D | 1 |
| Braillard, S | 1 |
| Wan, B | 1 |
| Franzblau, SG | 1 |
| Ma, Z | 1 |
| Cooper, CB | 1 |
| Denny, WA | 1 |
| Saccoliti, F | 1 |
| Madia, VN | 1 |
| Tudino, V | 1 |
| De Leo, A | 1 |
| Pescatori, L | 1 |
| Messore, A | 1 |
| De Vita, D | 1 |
| Scipione, L | 1 |
| Mäser, P | 1 |
| Calvet, CM | 1 |
| Jennings, GK | 1 |
| Podust, LM | 1 |
| Costi, R | 1 |
| Di Santo, R | 1 |
| Martín-Escolano, R | 1 |
| Marín, C | 1 |
| Vega, M | 1 |
| Martin-Montes, Á | 1 |
| Medina-Carmona, E | 1 |
| López, C | 1 |
| Rotger, C | 1 |
| Costa, A | 1 |
| Sánchez-Moreno, M | 1 |
| Wang, X | 1 |
| Cal, M | 1 |
| Buckner, FS | 1 |
| Lepesheva, GI | 1 |
| Sanford, AG | 1 |
| Wallick, AI | 1 |
| Davis, PH | 1 |
| Vennerstrom, JL | 1 |
| Bouton, J | 1 |
| Ferreira de Almeida Fiuza, L | 1 |
| Cardoso Santos, C | 1 |
| Mazzarella, MA | 1 |
| Soeiro, MNC | 2 |
| Karalic, I | 2 |
| Caljon, G | 2 |
| Van Calenbergh, S | 2 |
| Lin, C | 1 |
| Jaén Batista, DDG | 1 |
| Mazzeti, AL | 1 |
| Donola Girão, R | 1 |
| de Oliveira, GM | 1 |
| Hulpia, F | 1 |
| Gulin, JEN | 1 |
| Bisio, MMC | 1 |
| Rocco, D | 1 |
| Altcheh, J | 1 |
| Solana, ME | 1 |
| García-Bournissen, F | 1 |
| Barrias, E | 1 |
| Reignault, LC | 1 |
| Calogeropoulou, T | 1 |
| de Souza, W | 1 |
| Benaim, B | 1 |
| Garcia, CR | 1 |
| Saraiva, VB | 1 |
| Gibaldi, D | 1 |
| Previato, JO | 1 |
| Mendonça-Previato, L | 1 |
| Bozza, MT | 1 |
| Freire-De-Lima, CG | 1 |
| Heise, N | 1 |
| Croft, SL | 1 |
| Snowdon, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
1 review available for miltefosine and Chagas Disease
| Article | Year |
|---|---|
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishman | 2011 |
18 other studies available for miltefosine and Chagas Disease
| Article | Year |
|---|---|
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
Topics: Animals; Benzimidazoles; Cell Line; Cell Survival; Chagas Disease; Glucose; Leishmania braziliensis; | 2009 |
Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
Topics: Amines; Animals; Cells, Cultured; Chagas Disease; Leishmania donovani; Mice; Nitro Compounds; Parasi | 2011 |
Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
Topics: Animals; Antiprotozoal Agents; Benzene; Chagas Disease; Female; Leishmania donovani; Mice; Mice, Inb | 2013 |
Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
Topics: Amides; Apoptosis; Blood Platelets; Cells, Cultured; Chagas Disease; Flow Cytometry; Heterocyclic Co | 2014 |
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line; Chagas Disease; Disease Models, Animal; Leishmania donovani; Mice | 2015 |
3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
Topics: Animals; Cell Line; Chagas Disease; Dose-Response Relationship, Drug; Humans; Leishmania donovani; M | 2015 |
Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
Topics: Amides; Antiprotozoal Agents; Cell Line; Chagas Disease; Humans; Leishmania; Parasitic Sensitivity T | 2016 |
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
Topics: Antiprotozoal Agents; Chagas Disease; Dose-Response Relationship, Drug; Humans; Macrophages; Molecul | 2018 |
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
Topics: Animals; Antiparasitic Agents; Cell Membrane Permeability; Chagas Disease; Cricetinae; Cytochrome P- | 2018 |
Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Chagas Disease; Female; Humans; Imidazoles; Inhibitory Con | 2018 |
Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
Topics: Animals; Chagas Disease; Chlorocebus aethiops; Cyclobutanes; DNA; Female; Membrane Potential, Mitoch | 2019 |
A new chemotype with promise against Trypanosoma cruzi.
Topics: Animals; Chagas Disease; Humans; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma c | 2020 |
Revisiting Pyrazolo[3,4-
Topics: Animals; Chagas Disease; Drug Design; Drug Stability; Humans; Leishmania infantum; Male; Mice; Micro | 2021 |
N
Topics: Animals; Chagas Disease; Leishmania; Mice; Nucleosides; Purines; Structure-Activity Relationship; Tr | 2022 |
Miltefosine and Benznidazole Combination Improve Anti-
Topics: Animals; Chagas Disease; Mice; Nitroimidazoles; Parasitemia; Phosphorylcholine; Trypanocidal Agents; | 2022 |
In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects.
Topics: Adamantane; Animals; Antiprotozoal Agents; Autophagy; Cell Membrane; Chagas Disease; Dose-Response R | 2019 |
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.
Topics: Animals; Antiprotozoal Agents; Chagas Disease; Drug Resistance; Exudates and Transudates; Inflammati | 2002 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |